clinical aspects for cell based therapies for cardiac
play

Clinical aspects for cell-based therapies for cardiac repair Pieter A. Doevendans UMC Utrecht The Netherlands Medical manager Division Heart and Lungs Representing the ESC within CAT Presented by: Name Surname CAT-DGTI-GSCN Workshop, 11

0 downloads 2 Views 1,63 MB Size Report
  1. Clinical aspects for cell-based therapies for cardiac repair Pieter A. Doevendans UMC Utrecht The Netherlands Medical manager Division Heart and Lungs Representing the ESC within CAT Presented by: Name Surname CAT-DGTI-GSCN Workshop, 11 September 2014, Dresden An agency of the European Union

  2. Efficacy of Stem cell applications? What we learned from clinical trials today! - Not clear when, what, how and how much. - Much debate on efficacy and reliability of the data reported. - No standardization of products and assessments in vitro and in vivo . 1 CAT-DGTI-GSCN Workshop, Dresden, 11 September 2014

  3. 2 CAT-DGTI-GSCN Workshop, Dresden, 11 September 2014

  4. 3 CAT-DGTI-GSCN Workshop, Dresden, 11 September 2014

  5. Recommendations on imaging modalities in cardiac repair: Any method chosen to estimate LVEF must be used both for baseline as well as follow up Any method chosen for a trial should be the one used on all patients enrolled Change in infarct size should be evaluated by CT or MR. 256+ CT will probably be the modality of choice in the future but CMR is currently the gold standard 4 CAT-DGTI-GSCN Workshop, Dresden, 11 September 2014

  6. 5 CAT-DGTI-GSCN Workshop, Dresden, 11 September 2014

  7. 6 CAT-DGTI-GSCN Workshop, Dresden, 11 September 2014

  8. 7 CAT-DGTI-GSCN Workshop, Dresden, 11 September 2014

  9. Infarct size 8 CAT-DGTI-GSCN Workshop, Dresden, 11 September 2014

  10. 9 CAT-DGTI-GSCN Workshop, Dresden, 11 September 2014

  11. 10 CAT-DGTI-GSCN Workshop, Dresden, 11 September 2014

  12. Diagnosis of myocardial infarction BAMI protocol Primary Angioplasty <12 hours Days 3-5 Echocardiogram EF<45%  3000 patient outcome study  End–point = 25 % reduction in death (all cause at 2 years) BM Aspiration 100mls  STANDARDISATION of cell Days 5-8 Repeat processing technique Standard care Angiography BMMNC infusion 2 years Study end-point - mortality

  13. Over 1700 pts in 33 trials 13 CAT-DGTI-GSCN Workshop, Dresden, 11 September 2014

  14. Discrepancies vs functional outcome 14 CAT-DGTI-GSCN Workshop, Dresden, 11 September 2014

  15. Effect vs discrepancies 15 CAT-DGTI-GSCN Workshop, Dresden, 11 September 2014

  16. Conclusions With unselected and selected BMMNC: significant but very limited effect on Left Ventricular volumes and infarct size. Very limited effect on mortality reduction; Outcome BAMI trial? Not enough data on other cell sources yet to make firm statements. Lack of standardization: product, dosage; application mode; assessment of efficacy clinical and preclinical 16 CAT-DGTI-GSCN Workshop, Dresden, 11 September 2014

  17. 17 CAT-DGTI-GSCN Workshop, Dresden, 11 September 2014

  18. Morphology: Infarct size MRI LGE Caduceus: cardiospheres Scipio: cardiac stem cells

Recommend Documents


cell based therapies for cardiac repair
Cell-based therapies for cardiac repair

Cell-based therapies for cardiac repair NON-CLINICAL ASPECTS Presented by:

unproven cell based therapies a risk to public health and
Unproven cell-based therapies: a risk

Unproven cell-based therapies: a risk to public health and to the development

quality aspects for cell based products for cardiac repair
Quality aspects for cell-based products

Quality aspects for cell-based products for cardiac repair CAT-DGTI Workshop

clinical development and innovation in engineered t cell
Clinical Development and Innovation in

Clinical Development and Innovation in Engineered T Cell Therapies Bruce

standards coordinating body
Standards Coordinating Body For

Standards Coordinating Body For Cellular/Gene and Regenerative Therapies and

regulation of cell and tissue therapies and clinical
Regulation of cell and tissue therapies

Regulation of cell and tissue therapies and clinical research in Australia

reflection paper on stem cell based medicinal products
Reflection paper on stem cell based

Reflection paper on stem cell based medicinal products - introduction

breakthrough stem cell therapies for sci
Breakthrough Stem Cell Therapies

Breakthrough Stem Cell Therapies for SCI Dr. Kim Anderson-Erisman

overview of regulation of stem cell based products by the
Overview of Regulation of Stem

Overview of Regulation of Stem Cell-Based Products by the U.S. FDA EMA Stem

care of cardiac and non cardiac patients
Care of cardiac and non cardiac

Care of cardiac and non cardiac patients Niall Herity MD Consultant

medical tourism
Medical Tourism: Some Lessons for

Medical Tourism: Some Lessons for Countries that Seek Entrance to the Global

modern approach in posttraumatic carotid cavernous
Modern approach in posttraumatic

02 RJR 02 2011.qxd:Interior 4/26/11 11:57 AM Page 85 Romanian Journal of

genesis
Genesis Nicolas W Shammas, MD, MS,

Highlights of Cardiology Research At Genesis Nicolas W Shammas, MD, MS, FACC

2 19 2020
2/19/2020 HEMODYNAMIC SUPPORT IN

2/19/2020 HEMODYNAMIC SUPPORT IN ACUTE CARDIOGENIC SHOCK Catherine T.

medical device rew a clinician s perspective
MEDICAL DEVICE REW a clinicians

MEDICAL DEVICE REW a clinicians perspective INTERNATIONAL MEDICAL DEVICE

2016 financial year
2016 financial year Yves Serra

Annual Media Conference 2016 financial year Yves Serra 28.02.2017 GF

defuse and defuse 2
DEFUSE and DEFUSE 2 Patients with

DEFUSE and DEFUSE 2 Patients with Target mismatch profile have a powerful

do adjuncts improve durability
Do Adjuncts Improve Durability of

Do Adjuncts Improve Durability of POSE? Robert Fisher LiVES Royal Liverpool

a training guide for women with diabetes
A training guide for women with

PREGNANCY: THE KIDNEY MARATHON A training guide for women with diabetes

hypertension peripheral artery disease pad
Hypertension Peripheral artery

Hypertension Peripheral artery disease (PAD) D.L.Clement, Ghent, Belgium

efficacy and safety of a novel antihypertensive
Efficacy and Safety of a Novel

Novel Evaluation With QGC001 in Hypertensive Overweight Patients of Multiple

a leader redefining how kidney disease is treated
A Leader Redefining How Kidney Disease

A Leader Redefining How Kidney Disease is Treated Investor Presentation July